期刊
ACS APPLIED MATERIALS & INTERFACES
卷 12, 期 51, 页码 56701-56711出版社
AMER CHEMICAL SOC
DOI: 10.1021/acsami.0c13825
关键词
BSA nanocage; ultra-small iron oxide nanoparticles; T-1 contrast agent; magnetic resonance angiography; biocompatibility; renal clearance
资金
- National Natural Science Foundation of China [3190110313, U1632274, 8197102295, U1732157]
- Ministry of Science and Technology of China [2016YFA0400901]
- High Magnetic Field Laboratory of Anhui Province
Ultra-small-sized iron oxide nanoparticles with good biocompatibility are regarded as promising alternatives for the gadolinium-based contrast agents, which are widely used as a positive contrast agent in magnetic resonance imaging (MRI). However, the current preparation of the iron oxide magnetic nanoparticles with small sizes usually involves organic solvents, increasing the complexity of hydrophilic ligand replacement and reducing the synthesis efficiency. It remains a great challenge to explore new iron oxide nanoparticles with good biocompatibility and a high T-1 contrast effect. Here, we reported a cage-like protein architecture self-assembled by approximately 6-7 BSA (bovine serum albumin) subunits. The BSA nanocage was then used as a biotemplate to synthesize uniformed and monodispersed Fe2O3@BSA nanoparticles with ultra-small sizes (similar to 3.5 nm). The Fe2O3@BSA nanoparticle showed a high r(1) value of 6.8 mM(-1)s(-1) and a low r(2)/r(1) ratio of 10.6 at a 3 T magnetic field. Compared to Gd-DTPA, the brighter signal and prolonged angiographic effect of Fe2O3@BSA nanoparticles could greatly benefit steady-state and high-resolution imaging. The further in vivo and in vitro assessments of stability, toxicity, and renal clearance indicated a substantial potential as a T-1 contrast agent in preclinical MRI.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据